Yahoo Web Search

Search results

1. • Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

     The Record Gazette· 6 days ago

     Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.)

2. • 

     The bird flu vaccine is made with eggs. That has scientists worried.

     CBS News· 1 day ago

     "It's almost comical to be using a 1940s technology for a 21st-century pandemic," said Rick Bright,...

3. • 

     BTK Inhibitor Likely to Get a Pass to Phase III in Uncontrolled Asthma

     MedPage Today· 6 days ago

     Rilzabrutinib was also associated with improved disease control on the 5-item Asthma Control...

4. • Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible...

     Benzinga· 3 days ago

     The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab) in combination ...

5. • The Trump policy Biden won’t kill

     Politico· 21 hours ago

     Supply shortages, which manufacturers attributed to underestimating demand, led the CDC to urge providers to ration the shots. RSV sends 58,000 to 80,000 children under age 5 to the hospital ...

6. • Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

     Fairfield-Suisun Daily Republic· 6 days ago

     Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.)

7. • 

     Biotech faces a reckoning: ‘We've lost our luster in cell therapies’

     FierceBiotech· 20 hours ago

     This story is the first part in a four-part series about cell therapy, created by the Fierce Biotech...

8. • Zantac Not a Cause of Woman’s Cancer, Jury Says in First Trial Over Drug

     US News & World Report· 7 days ago

     CHICAGO (Reuters) -A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands ...

9. • Idorsia’s Jean-Paul Clozel retires as CEO, plots next steps; CRISPR Therapeutics nabs CMO from ...

     Endpoints News· 6 days ago

     → Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether. Jörn Aldag, Felix Ehrat and Peter Kellogg are stepping ...

10. • 

      2 Biotech Stocks to Buy in May

      Motley Fool via Yahoo Finance· 5 days ago

      The biotech's current biggest growth driver, though, is Dupixent, a medicine for eczema. Regeneron co-markets Dupixent withSanofi. The drug's global...